2,332 Shares in Danaher Corporation $DHR Acquired by Tyche Wealth Partners LLC

Tyche Wealth Partners LLC acquired a new stake in Danaher Corporation (NYSE:DHR) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 2,332 shares of the conglomerate’s stock, valued at approximately $462,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. White Pine Capital LLC grew its position in shares of Danaher by 1.4% during the 2nd quarter. White Pine Capital LLC now owns 3,494 shares of the conglomerate’s stock worth $690,000 after buying an additional 49 shares during the period. SOL Capital Management CO raised its position in shares of Danaher by 2.8% in the 3rd quarter. SOL Capital Management CO now owns 1,829 shares of the conglomerate’s stock valued at $363,000 after acquiring an additional 50 shares during the period. Purkiss Capital Advisors LLC boosted its stake in Danaher by 3.9% during the 3rd quarter. Purkiss Capital Advisors LLC now owns 1,327 shares of the conglomerate’s stock worth $263,000 after acquiring an additional 50 shares during the last quarter. Boyd Watterson Asset Management LLC OH grew its holdings in Danaher by 2.1% during the second quarter. Boyd Watterson Asset Management LLC OH now owns 2,524 shares of the conglomerate’s stock valued at $499,000 after purchasing an additional 51 shares during the period. Finally, Howard Capital Management Group LLC increased its stake in Danaher by 4.8% in the third quarter. Howard Capital Management Group LLC now owns 1,159 shares of the conglomerate’s stock valued at $230,000 after purchasing an additional 53 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

DHR has been the subject of several research analyst reports. Jefferies Financial Group boosted their price target on shares of Danaher from $255.00 to $265.00 and gave the company a “buy” rating in a report on Wednesday. TD Cowen reissued a “buy” rating on shares of Danaher in a research note on Wednesday, January 7th. Wells Fargo & Company raised their price target on Danaher from $230.00 to $240.00 and gave the stock an “equal weight” rating in a research report on Monday, December 15th. Rothschild & Co Redburn reiterated a “neutral” rating and set a $220.00 price objective (down previously from $245.00) on shares of Danaher in a report on Wednesday, October 8th. Finally, HSBC increased their target price on Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a research note on Monday, December 1st. Twenty analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and an average target price of $252.32.

Insiders Place Their Bets

In other news, SVP Georgeann Couchara sold 5,174 shares of the stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the completion of the transaction, the senior vice president directly owned 2,625 shares in the company, valued at $552,352.50. This represents a 66.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Brian W. Ellis sold 21,776 shares of Danaher stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total value of $4,773,952.48. Following the completion of the sale, the senior vice president directly owned 14,553 shares in the company, valued at approximately $3,190,454.19. This represents a 59.94% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 30,248 shares of company stock valued at $6,609,663 in the last three months. 11.10% of the stock is currently owned by corporate insiders.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Q4 results beat on EPS and management set FY2026 EPS guidance of $8.35–$8.50, which is above many street estimates and supports upside to earnings expectations. Danaher (DHR) Tops Q4 Earnings Estimates, Issues Solid 2026 Outlook
• Positive Sentiment: JPMorgan raised its price target to $275 and kept an overweight rating, signaling continued bullish sentiment among some large sell‑side shops. Benzinga
• Positive Sentiment: Molecular Devices (a Danaher business) announced a partnership to expand automated, AI‑ready research solutions — a product/market development that supports longer‑term growth in lab automation and software‑enabled sales. Molecular Devices Expands Access to Automated, AI-Ready Research Solutions
• Neutral Sentiment: Goldman Sachs trimmed its target slightly to $265 but maintained a buy rating, a modest calibration that still implies material upside but signals some caution. MarketScreener
• Neutral Sentiment: Earnings call transcripts and highlights show management emphasizing free cash flow and balance sheet strength, but a cautious tone on near‑term demand. These details provide context but are not unambiguously positive or negative. Danaher (DHR) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Market commentary and headlines framed the report as “in‑line” on sales and cautioned investors that the post‑earnings dip may not be a good buying opportunity, which likely amplified selling pressure. Danaher Stock Plunge Does Not Represent A Good Entry Point
• Negative Sentiment: Despite the EPS beat, some outlets highlighted the stock drop after an essentially in‑line revenue/outlook, reinforcing bearish sentiment in the short term. Danaher drops after in-line earnings outlook
• Negative Sentiment: Valuation is elevated (P/E ~43) versus historical averages, which can make the stock more sensitive to any guidance softness or mixed indicators.

Danaher Stock Down 0.4%

Shares of Danaher stock opened at $218.82 on Friday. The firm has a market cap of $154.56 billion, a PE ratio of 43.42, a P/E/G ratio of 3.12 and a beta of 0.89. The business’s 50 day simple moving average is $230.60 and its 200 day simple moving average is $213.96. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.10 and a current ratio of 1.87. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $242.80.

Danaher (NYSE:DHR) last released its quarterly earnings results on Wednesday, January 28th. The conglomerate reported $2.23 earnings per share for the quarter, topping analysts’ consensus estimates of $2.14 by $0.09. Danaher had a return on equity of 10.81% and a net margin of 14.71%.The firm had revenue of $6.84 billion during the quarter, compared to the consensus estimate of $6.79 billion. During the same quarter in the prior year, the firm posted $2.14 EPS. The business’s revenue was up 4.6% on a year-over-year basis. Danaher has set its FY 2026 guidance at 8.350-8.500 EPS. On average, analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, January 30th. Shareholders of record on Friday, December 26th were paid a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.6%. The ex-dividend date was Friday, December 26th. Danaher’s payout ratio is presently 25.40%.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.